Publication: Addition of silymarin to renin-angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial
dc.contributor.coauthor | Voroneanu, Luminita | |
dc.contributor.coauthor | Siriopol, Dimitrie | |
dc.contributor.coauthor | Dumea, Raluca | |
dc.contributor.coauthor | Badarau, Silvia | |
dc.contributor.coauthor | Afşar, Barış | |
dc.contributor.coauthor | Gavrilovici, Cristina | |
dc.contributor.coauthor | Covic, Adrian | |
dc.contributor.department | School of Medicine | |
dc.contributor.kuauthor | Kanbay, Mehmet | |
dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
dc.date.accessioned | 2024-11-09T22:51:55Z | |
dc.date.issued | 2017 | |
dc.description.abstract | Background : In the last decade, despite constant investigation, no current single treatment has been able to decrease the incidence of diabetic nephropathy and to significantly reduce progression of diabetic CKD. Methods : Patients with type 2 diabetes mellitus and proteinuria (> 0.5 g/day) after a screening and treatment optimization phase were randomly assigned to receive silymarin or placebo. The primary outcome was a composite outcome: mortality, decline of eGFR > 50% and renal replacement therapy. Secondary outcomes were a composite renal outcome (defined as a decline of eGFR >= 50% or ESRD) and also to test the effect of silymarin on the change in eGFR and proteinuria. We also assessed the adverse effects (hospitalizations, headache or gastrointestinal symptoms) during the study. Results : One hundred and two patients were included in the study. There were no significant differences between the two study groups regarding the primary and renal outcomes (HR 0.62, 95% CI 0.3-1.2, p = 0.15; HR 0.56, 95% CI 0.26-1.24, p = 0.16, respectively). At study end, eGFR declined significantly in both arms (p < 0.001), irrespective of the treatment group allocation, and there were no significant changes in proteinuria. There was a significant difference in hospitalizations rates between the two study groups (0.61, 95% CI 0.44-0.85). Conclusions : Silymarin did not show a significant reduction in the primary and secondary outcomes. Importantly, silymarin treatment was associated with a significant reduction in the hospitalization rate. | |
dc.description.indexedby | WOS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 12 | |
dc.description.openaccess | NO | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.volume | 49 | |
dc.identifier.doi | 10.1007/s11255-017-1697-5 | |
dc.identifier.eissn | 1573-2584 | |
dc.identifier.issn | 0301-1623 | |
dc.identifier.quartile | Q3 | |
dc.identifier.scopus | 2-s2.0-85029819339 | |
dc.identifier.uri | https://doi.org/10.1007/s11255-017-1697-5 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/6935 | |
dc.identifier.wos | 414377800016 | |
dc.keywords | Silymarin | |
dc.keywords | Chronic kidney disease | |
dc.keywords | Diabetes mellitus | |
dc.keywords | Proteinuria | |
dc.keywords | Survival | |
dc.language.iso | eng | |
dc.publisher | Springer | |
dc.relation.ispartof | International Urology and Nephrology | |
dc.subject | Urology | |
dc.subject | Nephrology | |
dc.title | Addition of silymarin to renin-angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial | |
dc.type | Journal Article | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Kanbay, Mehmet | |
local.publication.orgunit1 | SCHOOL OF MEDICINE | |
local.publication.orgunit2 | School of Medicine | |
relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |